YD Bio Ltd·4

Jul 1, 3:33 PM ET

Lu Shao-Ta 4

4 · YD Bio Ltd · Filed Jul 1, 2026

Research Summary

AI-generated summary of this filing

Updated

YD Bio (YDES) Director Lu Shao‑Ta Receives 5,749 RSUs (Converted)

What Happened

  • Director Lu Shao‑Ta received 5,749 restricted share units (RSUs) that vested on June 30, 2026 and were converted/exercised into 5,749 ordinary shares. The RSUs had no cash exercise price (reported $0.00); the original aggregate target grant‑date fair value for the granted RSUs was $60,000 (granted March 31, 2026).
  • This was an award/vesting event and conversion of the derivative RSUs into shares, not a market purchase or sale of ordinary shares. The filing shows both the award (code A) and the conversion/exercise (code M); the reported disposition (code M) reflects cancellation/conversion of the derivative RSUs rather than a public sale of shares.

Key Details

  • Transaction date: 2026-06-30. Report filed: 2026-07-01 (appears timely).
  • Reported amounts/prices: 5,749 RSUs awarded (A) @ $0.00; conversion/exercise (M) to 5,749 shares @ $0.00. Grant target fair value on March 31, 2026 was $60,000.
  • Shares owned after transaction: not specified in the provided data.
  • Footnotes: F1 defines RSUs as contingent rights to one ordinary share each; F2 describes the Equity Incentive Plan grant mechanics and $15,000-per-quarter sizing method; F3 confirms the RSUs became a fixed entitlement on the June 30 vesting date.
  • Transaction codes: A = Award/Grant, M = Exercise/Conversion. No 10b5‑1 or tax‑withholding details were disclosed in the provided extract.

Context

  • For retail investors: this is a routine equity‑compensation vesting and conversion event, not an open‑market purchase or sale. Because the RSUs converted at $0 exercise price and were part of compensation, this does not necessarily signal buying/selling intent by the insider.
  • The grant’s target fair value ($60k at grant) gives a sense of economic size, but the actual number of RSUs was determined by a VWAP‑based formula described in the footnote.

Insider Transaction Report

Form 4
Period: 2026-06-30
Lu Shao-Ta
Director
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-06-30+5,7497,830 total
  • Award

    Restricted Share Units

    [F1][F2][F3]
    2026-06-30+5,7495,749 total
    Ordinary Shares (5,749 underlying)
  • Exercise/Conversion

    Restricted Share Units

    [F1][F2]
    2026-06-305,7490 total
    Ordinary Shares (5,749 underlying)
Holdings
  • Ordinary Shares

    (indirect: By Spouse)
    51,151
Footnotes (3)
  • [F1]Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
  • [F2]The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.
  • [F3]The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").
Signature
/s/ Shao-Ta Lu|2026-07-01

Documents

1 file
  • 4
    ownership.xmlPrimary